{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:28:45Z","timestamp":1791264525267,"version":"4.1.0"},"reference-count":100,"publisher":"The Endocrine Society","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,12,1]]},"DOI":"10.1210\/jc.2007-0646","type":"journal-article","created":{"date-parts":[[2007,9,26]],"date-time":"2007-09-26T02:24:32Z","timestamp":1190773472000},"page":"4514-4521","source":"Crossref","is-referenced-by-count":196,"title":["The Role of Receptor Activator of Nuclear Factor-\u03baB (RANK)\/RANK Ligand\/Osteoprotegerin: Clinical Implications"],"prefix":"10.1210","volume":"92","author":[{"given":"Damaris","family":"Vega","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and Charles and Jane Pak Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center, Dallas, Texas 75390"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naim M.","family":"Maalouf","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Charles and Jane Pak Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center, Dallas, Texas 75390"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khashayar","family":"Sakhaee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Charles and Jane Pak Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center, Dallas, Texas 75390"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"key\n\t\t\t\t2019041114115170300_R1","year":"2006"},{"key":"key\n\t\t\t\t2019041114115170300_R2","first-page":"115","article-title":"Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis.","volume":"21","author":"Manolagas","year":"2000","journal-title":"Endocr Rev"},{"key":"key\n\t\t\t\t2019041114115170300_R3","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.1210\/endo.140.10.7129","article-title":"Cell number versus cell vigor: what really matters to a regenerating skeleton?","volume":"140","author":"Manolagas","year":"1999","journal-title":"Endocrinology"},{"key":"key\n\t\t\t\t2019041114115170300_R4","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.bone.2005.07.004","article-title":"Differences in osteocyte and lacunar density between Black and White American women.","volume":"38","author":"Qiu","year":"2006","journal-title":"Bone"},{"key":"key\n\t\t\t\t2019041114115170300_R5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1138\/20060193","article-title":"Choreography from the tomb: an emerging role of dying osteocytes in the purposeful, and perhaps not so purposeful, targeting of bone remodeling.","volume":"3","author":"Manolagas","year":"2006","journal-title":"BoneKey-Osteovision"},{"key":"key\n\t\t\t\t2019041114115170300_R6","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00223-001-1024-z","article-title":"Do bone cells behave like a neuronal network?","volume":"70","author":"Turner","year":"2002","journal-title":"Calcif Tissue Int"},{"key":"key\n\t\t\t\t2019041114115170300_R7","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0021-9290(03)00126-X","article-title":"Strain-derived canalicular fluid flow regulates osteoclast activity in a remodelling osteon: a proposal.","volume":"36","author":"Burger","year":"2003","journal-title":"J Biomech"},{"key":"key\n\t\t\t\t2019041114115170300_R8","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/35015116","article-title":"Effects of mechanical forces on maintenance and adaptation of form in trabecular bone.","volume":"405","author":"Huiskes","year":"2000","journal-title":"Nature"},{"key":"key\n\t\t\t\t2019041114115170300_R9","first-page":"66","article-title":"Modulation of osteoclast differentiation.","volume":"13","author":"Suda","year":"1992","journal-title":"Endocr Rev"},{"key":"key\n\t\t\t\t2019041114115170300_R10","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1084\/jem.188.5.997","article-title":"TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts.","volume":"188","author":"Fuller","year":"1998","journal-title":"J Exp Med"},{"key":"key\n\t\t\t\t2019041114115170300_R11","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1006\/bbrc.1998.8586","article-title":"Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures.","volume":"246","author":"Matsuzaki","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"key\n\t\t\t\t2019041114115170300_R12","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"key":"key\n\t\t\t\t2019041114115170300_R13","doi-asserted-by":"crossref","first-page":"434","DOI":"10.4049\/jimmunol.163.1.434","article-title":"Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function.","volume":"163","author":"Jimi","year":"1999","journal-title":"J Immunol"},{"key":"key\n\t\t\t\t2019041114115170300_R14","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1083\/jcb.145.3.527","article-title":"The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.","volume":"145","author":"Burgess","year":"1999","journal-title":"J Cell Biol"},{"key":"key\n\t\t\t\t2019041114115170300_R15","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.biocel.2006.11.008","article-title":"RANK ligand.","volume":"39","author":"Blair","year":"2007","journal-title":"Int J Biochem Cell Biol"},{"key":"key\n\t\t\t\t2019041114115170300_R16","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1073\/pnas.96.7.3540","article-title":"Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand.","volume":"96","author":"Hsu","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"key\n\t\t\t\t2019041114115170300_R17","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1006\/mthe.2001.0245","article-title":"Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis.","volume":"3","author":"Bolon","year":"2001","journal-title":"Mol Ther"},{"key":"key\n\t\t\t\t2019041114115170300_R18","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"key":"key\n\t\t\t\t2019041114115170300_R19","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/jbmr.5650110802","article-title":"Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis.","volume":"11","author":"Pacifici","year":"1996","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041114115170300_R20","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S8756-3282(98)00077-5","article-title":"Cytokines, bone remodeling, and estrogen deficiency: a 1998 update.","volume":"23","author":"Jilka","year":"1998","journal-title":"Bone"},{"key":"key\n\t\t\t\t2019041114115170300_R21","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJM199502023320506","article-title":"Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis.","volume":"332","author":"Manolagas","year":"1995","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041114115170300_R22","doi-asserted-by":"crossref","first-page":"4367","DOI":"10.1210\/endo.140.9.7131","article-title":"Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells.","volume":"140","author":"Hofbauer","year":"1999","journal-title":"Endocrinology"},{"key":"key\n\t\t\t\t2019041114115170300_R23","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1172\/JCI200317215","article-title":"Role of RANK ligand in mediating increased bone resorption in early postmenopausal women.","volume":"111","author":"Eghbali-Fatourechi","year":"2003","journal-title":"J Clin Invest"},{"key":"key\n\t\t\t\t2019041114115170300_R24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00223-004-0007-2","article-title":"Relationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20\u201375.","volume":"76","author":"Liu","year":"2005","journal-title":"Calcif Tissue Int"},{"key":"key\n\t\t\t\t2019041114115170300_R25","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1365-2265.2005.02221.x","article-title":"The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone.","volume":"62","author":"Han","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"key":"key\n\t\t\t\t2019041114115170300_R26","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.1210\/jc.2002-020396","article-title":"Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women.","volume":"87","author":"Rogers","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041114115170300_R27","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1210\/endo.140.10.7034","article-title":"Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis.","volume":"140","author":"Hofbauer","year":"1999","journal-title":"Endocrinology"},{"key":"key\n\t\t\t\t2019041114115170300_R28","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S8756-3282(02)00742-1","article-title":"Changes in osteoprotegerin and markers of bone metabolism during glucocorticoid treatment in patients with chronic glomerulonephritis.","volume":"30","author":"Sasaki","year":"2002","journal-title":"Bone"},{"key":"key\n\t\t\t\t2019041114115170300_R29","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1097\/00042737-200311000-00003","article-title":"Effect of systemic glucocorticoid therapy on bone metabolism and the osteoprotegerin system in patients with active Crohn\u2019s disease.","volume":"15","author":"von Tirpitz","year":"2003","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t2019041114115170300_R30","first-page":"20","article-title":"The role of the synovial fibroblast in rheumatoid arthritis: cartilage destruction and the regulation of matrix metalloproteinases.","volume":"64","author":"Abeles","year":"2006","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"key\n\t\t\t\t2019041114115170300_R31","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.clim.2004.12.009","article-title":"The fibroblast-like synovial cell in rheumatoid arthritis: a key player in inflammation and joint destruction.","volume":"115","author":"Mor","year":"2005","journal-title":"Clin Immunol"},{"key":"key\n\t\t\t\t2019041114115170300_R32","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/36593","article-title":"A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.","volume":"390","author":"Anderson","year":"1997","journal-title":"Nature"},{"key":"key\n\t\t\t\t2019041114115170300_R33","doi-asserted-by":"crossref","first-page":"25190","DOI":"10.1074\/jbc.272.40.25190","article-title":"TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells.","volume":"272","author":"Wong","year":"1997","journal-title":"J Biol Chem"},{"key":"key\n\t\t\t\t2019041114115170300_R34","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1002\/1529-0131(200011)43:11<2523::AID-ANR20>3.0.CO;2-Z","article-title":"Expression of osteoclast differentiation factor in rheumatoid arthritis.","volume":"43","author":"Shigeyama","year":"2000","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019041114115170300_R35","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1002\/art.10388","article-title":"High levels of osteoprotegerin and soluble receptor activator of nuclear factor \u03baB ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor \u03b1 treatment.","volume":"46","author":"Ziolkowska","year":"2002","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019041114115170300_R36","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1056\/NEJM197411142912001","article-title":"Evidence for the secretion of an osteoclast stimulating factor in myeloma.","volume":"291","author":"Mundy","year":"1974","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041114115170300_R37","first-page":"5438","article-title":"Receptor activator of nuclear factor-\u03baB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo.","volume":"63","author":"Farrugia","year":"2003","journal-title":"Cancer Res"},{"key":"key\n\t\t\t\t2019041114115170300_R38","doi-asserted-by":"crossref","first-page":"11581","DOI":"10.1073\/pnas.201394498","article-title":"Multiple myeloma disrupts the TRANCE\/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression.","volume":"98","author":"Pearse","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"key\n\t\t\t\t2019041114115170300_R39","doi-asserted-by":"crossref","first-page":"4646","DOI":"10.1182\/blood-2002-01-0148","article-title":"Immunocytochemistry reveals RANKL expression of myeloma cells.","volume":"99","author":"Sezer","year":"2002","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041114115170300_R40","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1182\/blood.V98.13.3527","article-title":"Myeloma cells induce imbalance in the osteoprotegerin\/osteoprotegerin ligand system in the human bone marrow environment.","volume":"98","author":"Giuliani","year":"2001","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041114115170300_R41","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.1182\/blood-2002-04-1121","article-title":"Human myeloma cells stimulate the receptor activator of nuclear factor-\u03baB ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease.","volume":"100","author":"Giuliani","year":"2002","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041114115170300_R42","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00223-002-2070-x","article-title":"Low bone mineral density in the hip as a marker of advanced atherosclerosis in elderly women.","volume":"73","author":"Tanko","year":"2003","journal-title":"Calcif Tissue Int"},{"key":"key\n\t\t\t\t2019041114115170300_R43","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2310\/6650.2006.06019","article-title":"Role of osteoprotegerin and its ligands and competing receptors in atherosclerotic calcification.","volume":"54","author":"Tintut","year":"2006","journal-title":"J Investig Med"},{"key":"key\n\t\t\t\t2019041114115170300_R44","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00198-006-0282-z","article-title":"Vascular calcification and osteoporosis-from clinical observation towards molecular understanding.","volume":"18","author":"Hofbauer","year":"2007","journal-title":"Osteoporos Int"},{"key":"key\n\t\t\t\t2019041114115170300_R45","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1210\/jc.2003-031432","article-title":"Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-\u03baB ligand in Monckeberg\u2019s sclerosis and atherosclerosis.","volume":"89","author":"Schoppet","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041114115170300_R46","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00198-003-1550-9","article-title":"Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels.","volume":"15","author":"Pennisi","year":"2004","journal-title":"Osteoporos Int"},{"key":"key\n\t\t\t\t2019041114115170300_R47","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/BF02390833","article-title":"Bone loss and the progression of abdominal aortic calcification over a 25 year period: the Framingham Heart Study.","volume":"68","author":"Kiel","year":"2001","journal-title":"Calcif Tissue Int"},{"key":"key\n\t\t\t\t2019041114115170300_R48","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1161\/01.STR.28.9.1730","article-title":"Bone changes and carotid atherosclerosis in postmenopausal women.","volume":"28","author":"Uyama","year":"1997","journal-title":"Stroke"},{"key":"key\n\t\t\t\t2019041114115170300_R49","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1210\/er.2003-0015","article-title":"Molecular, endocrine, and genetic mechanisms of arterial calcification.","volume":"25","author":"Doherty","year":"2004","journal-title":"Endocr Rev"},{"key":"key\n\t\t\t\t2019041114115170300_R50","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1161\/01.ATV.0000133194.94939.42","article-title":"Vascular calcification: mechanisms and clinical ramifications.","volume":"24","author":"Abedin","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key\n\t\t\t\t2019041114115170300_R51","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1161\/01.CIR.0000096485.64373.C5","article-title":"Multilineage potential of cells from the artery wall.","volume":"108","author":"Tintut","year":"2003","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019041114115170300_R52","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1161\/hq1201.100229","article-title":"Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques.","volume":"21","author":"Dhore","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key\n\t\t\t\t2019041114115170300_R53","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.yjmcc.2003.09.015","article-title":"Receptor activator of nuclear factor \u03baB ligand and osteoprotegerin regulate aortic valve calcification.","volume":"36","author":"Kaden","year":"2004","journal-title":"J Mol Cell Cardiol"},{"key":"key\n\t\t\t\t2019041114115170300_R54","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1084\/jem.192.4.463","article-title":"Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis.","volume":"192","author":"Min","year":"2000","journal-title":"J Exp Med"},{"key":"key\n\t\t\t\t2019041114115170300_R55","author":"McKusick","year":"2007"},{"key":"key\n\t\t\t\t2019041114115170300_R56","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1056\/NEJMoa013096","article-title":"Osteoprotegerin deficiency and juvenile Paget\u2019s disease.","volume":"347","author":"Whyte","year":"2002","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041114115170300_R57","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/71667","article-title":"Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis.","volume":"24","author":"Hughes","year":"2000","journal-title":"Nat Genet"},{"key":"key\n\t\t\t\t2019041114115170300_R58","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1359\/jbmr.2003.18.8.1381","article-title":"Phenotypic characterization of early onset Paget\u2019s disease of bone caused by a 27-bp duplication in the TNFRSF11A gene.","volume":"18","author":"Nakatsuka","year":"2003","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041114115170300_R59","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1359\/jbmr.2000.15.12.2330","article-title":"Expansile skeletal hyperphosphatasia: a new familial metabolic bone disease.","volume":"15","author":"Whyte","year":"2000","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041114115170300_R60","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1359\/jbmr.2002.17.1.26","article-title":"Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis.","volume":"17","author":"Whyte","year":"2002","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041114115170300_R61","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/00005792-200203000-00002","article-title":"Familial expansile osteolysis (excessive RANK effect) in a 5-generation American kindred.","volume":"81","author":"Whyte","year":"2002","journal-title":"Medicine (Baltimore)"},{"key":"key\n\t\t\t\t2019041114115170300_R62","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1093\/clinchem\/47.8.1475","article-title":"Immuno-PCR assay for homodimeric osteoprotegerin.","volume":"47","author":"Furuya","year":"2001","journal-title":"Clin Chem"},{"key":"key\n\t\t\t\t2019041114115170300_R63","doi-asserted-by":"crossref","first-page":"6323","DOI":"10.1210\/jc.2005-0794","article-title":"Circulating osteoprotegerin and receptor activator for nuclear factor \u03baB ligand: clinical utility in metabolic bone disease assessment.","volume":"90","author":"Rogers","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 6","key":"key\n\t\t\t\t2019041114115170300_R64","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1007\/s001980070004","article-title":"Preanalytical variability of biochemical markers of bone turnover","volume":"11","author":"Hannon","year":"2000","journal-title":"Osteoporos Int"},{"key":"key\n\t\t\t\t2019041114115170300_R65","first-page":"461","article-title":"Immunoassay for soluble RANKL (receptor activator of NF-\u03baB ligand) in serum.","volume":"49","author":"Hawa","year":"2003","journal-title":"Clin Lab"},{"key":"key\n\t\t\t\t2019041114115170300_R66","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S8756-3282(03)00090-5","article-title":"Serum levels of osteoprotegerin increase with age in a healthy adult population.","volume":"32","author":"Kudlacek","year":"2003","journal-title":"Bone"},{"key":"key\n\t\t\t\t2019041114115170300_R67","first-page":"409","article-title":"Circulating osteoprotegerin and leptin levels in postmenopausal women with and without osteoporosis.","volume":"41","author":"Grigorie","year":"2003","journal-title":"Rom J Intern Med"},{"key":"key\n\t\t\t\t2019041114115170300_R68","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s00198-003-1437-9","article-title":"Evidence that type I osteoporosis results from enhanced responsiveness of bone to estrogen deficiency.","volume":"14","author":"Riggs","year":"2003","journal-title":"Osteoporos Int"},{"key":"key\n\t\t\t\t2019041114115170300_R69","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1006\/bbrc.2001.5745","article-title":"Immunological study on circulating murine osteoprotegerin\/osteoclastogenesis inhibitory factor (OPG\/OCIF): possible role of OPG\/OCIF in the prevention of osteoporosis in pregnancy.","volume":"288","author":"Yano","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"key":"key\n\t\t\t\t2019041114115170300_R70","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s00774-003-0461-3","article-title":"Serum osteoprotegerin (OPG) and the A163G polymorphism in the OPG promoter region are related to peripheral measures of bone mass and fracture odds ratios.","volume":"22","author":"Jorgensen","year":"2004","journal-title":"J Bone Miner Metab"},{"key":"key\n\t\t\t\t2019041114115170300_R71","first-page":"631","article-title":"Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women.","volume":"86","author":"Browner","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041114115170300_R72","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/jama.291.9.1108","article-title":"Soluble RANKL and risk of nontraumatic fracture.","volume":"291","author":"Schett","year":"2004","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019041114115170300_R73","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1053\/ajkd.2002.31402","article-title":"Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure.","volume":"39","author":"Kazama","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t2019041114115170300_R74","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1677\/joe.0.1740353","article-title":"Serum osteoprotegerin\/osteoclastogenesis-inhibitory factor during pregnancy and lactation and the relationship with calcium-regulating hormones and bone turnover markers.","volume":"174","author":"Uemura","year":"2002","journal-title":"J Endocrinol"},{"key":"key\n\t\t\t\t2019041114115170300_R75","doi-asserted-by":"crossref","first-page":"5361","DOI":"10.1210\/jc.2003-030486","article-title":"Serum osteoprotegerin as a determinant of bone metabolism in a longitudinal study of human pregnancy and lactation.","volume":"88","author":"Naylor","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041114115170300_R76","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/pros.20016","article-title":"Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.","volume":"59","author":"Eaton","year":"2004","journal-title":"Prostate"},{"key":"key\n\t\t\t\t2019041114115170300_R77","first-page":"2977","article-title":"Serum osteoprotegerin levels are increased in patients with advanced prostate cancer.","volume":"7","author":"Brown","year":"2001","journal-title":"Clin Cancer Res"},{"key":"key\n\t\t\t\t2019041114115170300_R78","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1097\/01.ju.0000094191.39574.cb","article-title":"Serum osteoprotegerin and receptor activator of nuclear factor-\u03baB ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer.","volume":"170","author":"Jung","year":"2003","journal-title":"J Urol"},{"key":"key\n\t\t\t\t2019041114115170300_R79","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood.V98.7.2269","article-title":"Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease.","volume":"98","author":"Seidel","year":"2001","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041114115170300_R80","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1182\/blood-2002-04-1190","article-title":"Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells.","volume":"100","author":"Standal","year":"2002","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041114115170300_R81","first-page":"2306","article-title":"Serum osteoprotegerin levels in healthy controls and cancer patients.","volume":"8","author":"Lipton","year":"2002","journal-title":"Clin Cancer Res"},{"key":"key\n\t\t\t\t2019041114115170300_R82","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s10549-005-2419-8","article-title":"Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo: a role in tumour cell survival?","volume":"92","author":"Holen","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"key\n\t\t\t\t2019041114115170300_R83","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1677\/erc.1.00775","article-title":"Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole.","volume":"11","author":"Martinetti","year":"2004","journal-title":"Endocr Relat Cancer"},{"key":"key\n\t\t\t\t2019041114115170300_R84","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/ki.1993.64","article-title":"The spectrum of bone disease in end-stage renal failure: an evolving disorder.","volume":"43","author":"Sherrard","year":"1993","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t2019041114115170300_R85","first-page":"S72","article-title":"Incidence and clinical characteristics of hypoparathyroidism in dialysis patients","volume":"62","author":"Akizawa","year":"1997","journal-title":"Kidney Int Suppl"},{"key":"key\n\t\t\t\t2019041114115170300_R86","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/ndt\/17.2.233","article-title":"Serum osteoprotegerin and renal osteodystrophy.","volume":"17","author":"Coen","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t2019041114115170300_R87","doi-asserted-by":"crossref","first-page":"S175","DOI":"10.1053\/ajkd.2001.27437","article-title":"Osteoprotegerin levels before and after renal transplantation","volume":"38","author":"Sato","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t2019041114115170300_R88","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S8756-3282(02)00926-2","article-title":"Serum osteoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation.","volume":"32","author":"Fahrleitner","year":"2003","journal-title":"Bone"},{"key":"key\n\t\t\t\t2019041114115170300_R89","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/cncr.11138","article-title":"A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases.","volume":"97","author":"Body","year":"2003","journal-title":"Cancer"},{"key":"key\n\t\t\t\t2019041114115170300_R90","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.coph.2005.06.005","article-title":"Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.","volume":"5","author":"Kostenuik","year":"2005","journal-title":"Curr Opin Pharmacol"},{"key":"key\n\t\t\t\t2019041114115170300_R91","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1158\/1078-0432.CCR-05-1933","article-title":"A study of the biological receptor activator of nuclear factor-\u03baB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.","volume":"12","author":"Body","year":"2006","journal-title":"Clin Cancer Res"},{"key":"key\n\t\t\t\t2019041114115170300_R92","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1359\/jbmr.2001.16.2.348","article-title":"The effect of a single dose of osteoprotegerin in postmenopausal women.","volume":"16","author":"Bekker","year":"2001","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041114115170300_R93","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1359\/JBMR.040305","article-title":"A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women.","volume":"19","author":"Bekker","year":"2004","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041114115170300_R94","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density.","volume":"354","author":"McClung","year":"2006","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041114115170300_R95","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041114115170300_R96","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1056\/NEJMe068003","article-title":"The long and the short of bone therapy.","volume":"354","author":"Whyte","year":"2006","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041114115170300_R97","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1136\/jcp.2005.030031","article-title":"Expression of receptor activator of nuclear factor \u03b3\u03b2 ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables.","volume":"59","author":"Cross","year":"2006","journal-title":"J Clin Pathol"},{"key":"key\n\t\t\t\t2019041114115170300_R98","first-page":"1619","article-title":"Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.","volume":"62","author":"Holen","year":"2002","journal-title":"Cancer Res"},{"key":"key\n\t\t\t\t2019041114115170300_R99","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1023\/B:BREA.0000036900.48763.b3","article-title":"Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis.","volume":"86","author":"Neville-Webbe","year":"2004","journal-title":"Breast Cancer Res Treat"},{"key":"key\n\t\t\t\t2019041114115170300_R100","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/16852","article-title":"OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis.","volume":"397","author":"Kong","year":"1999","journal-title":"Nature"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/92\/12\/4514\/9051066\/jcem4514.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,18]],"date-time":"2024-02-18T04:00:07Z","timestamp":1708228807000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/92\/12\/4514\/2596621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12,1]]},"references-count":100,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2007,12,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2007-0646","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12,1]]}}}